191 related articles for article (PubMed ID: 34731510)
21. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
22. Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens.
Lu D; Gillespie WR; Girish S; Agarwal P; Li C; Hirata J; Chu YW; Kagedal M; Leon L; Maiya V; Jin JY
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):401-408. PubMed ID: 28544534
[TBL] [Abstract][Full Text] [Related]
23. [Proteins in haematology].
Clarenbach RE; Mey U
Ther Umsch; 2011 Nov; 68(11):610-7. PubMed ID: 22045523
[TBL] [Abstract][Full Text] [Related]
24. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
Mei M; Thomas S; Chen R
BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
[TBL] [Abstract][Full Text] [Related]
25. Sacituzumab govitecan activity in advanced breast cancer.
Burki TK
Lancet Oncol; 2017 May; 18(5):e246. PubMed ID: 28343977
[No Abstract] [Full Text] [Related]
26. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D
Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923
[TBL] [Abstract][Full Text] [Related]
27. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
[TBL] [Abstract][Full Text] [Related]
29. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
[TBL] [Abstract][Full Text] [Related]
30. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
31. Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.
Aguiar-Bujanda D; Dueñas-Comino A; Cabello C; Bastida J; Rivero-Vera JC; Limeres-González MA
Eur J Dermatol; 2017 Dec; 27(6):671-673. PubMed ID: 29165301
[No Abstract] [Full Text] [Related]
32. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.
Carella AM; Corradini P; Mussetti A; Ricardi U; Vitolo U; Viviani S
Ann Hematol; 2018 Aug; 97(8):1301-1315. PubMed ID: 29802458
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.
Fujimura T; Yamashita-Kashima Y; Kawasaki N; Yoshiura S; Harada N; Yoshimura Y
Mol Cancer Ther; 2021 Jun; 20(6):1133-1141. PubMed ID: 33850006
[TBL] [Abstract][Full Text] [Related]
34. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
35. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
36. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Saburi M; Sakata M; Kodama Y; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
J Clin Exp Hematop; 2023 Sep; 63(3):201-204. PubMed ID: 37518271
[No Abstract] [Full Text] [Related]
37. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T
Am J Hematol; 2021 Nov; 96(11):E423-E427. PubMed ID: 34383345
[No Abstract] [Full Text] [Related]
38. Axitinib-ICIs boost the RCC armamentarium.
Romero D
Nat Rev Clin Oncol; 2019 Apr; 16(4):207. PubMed ID: 30833679
[No Abstract] [Full Text] [Related]
39. The clinical conundrum of managing relapsed small cell lung cancer.
Nazha B; Owonikoko TK
Cancer; 2019 Apr; 125(7):1022-1026. PubMed ID: 30561759
[No Abstract] [Full Text] [Related]
40. [Epcoritamab - relapsed or refractory large diffuse B cells lymphoma after two or more lines of systemic therapy].
Bensaber H; Cacheux V
Bull Cancer; 2024 Jun; 111(6):544-545. PubMed ID: 38631985
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
